Unzyme Laboratories announces that DermaPlate Armor has received CE marking, clearing the path for commercial distribution across the European Economic Area. This regulatory milestone reflects the exceptional safety profile demonstrated throughout our clinical development program.
Advanced Protection Technology
DermaPlate Armor represents a significant advancement in dermal enhancement. Unlike traditional protective measures that add bulk or restrict movement, our system integrates directly with the patient’s existing dermal layers, providing enhanced resistance to mechanical damage while maintaining natural skin flexibility and sensation.
“The skin is our largest organ, yet enhancement options have historically been limited,” explains Dr. Yuki Tanaka, who leads our dermal research division. “DermaPlate changes that equation entirely. We’re providing protection that works with biology rather than against it.”
Clinical Evidence
Our European clinical program enrolled 612 participants across facilities in Germany, Finland, and the Netherlands. Key findings include:
- 340% improvement in puncture resistance
- 89% of participants reported no change in tactile sensitivity
- Integration time averaging 6-8 weeks
- Minimal procedural discomfort with local anesthesia
Market Availability
DermaPlate Armor will be available through our network of European dermatological partners beginning June 2021. Initial availability will focus on individuals with occupational exposure risks, with broader consumer access planned for late 2021.
Continued Development
Our dermal enhancement pipeline continues to expand. We are currently advancing DermaSeal technology, which will offer enhanced healing capabilities alongside the protective benefits of DermaPlate. We anticipate regulatory submissions within the next eighteen months.
We extend our appreciation to the clinical teams and participants who contributed to this achievement. Your partnership advances human capability for everyone.